Objectives: Minimally invasive mitral valve surgery (mini-MVR) has numerous associated benefits. However, many studies fail to include greater-risk patients. We hypothesized that a minimally invasive approach in a representative cohort provides excellent outcomes with reduced resource utilization.
hospital stays, and increased patient satisfaction. Moreover, the long-term durability appears equivalent to conventional mitral repair approaches. 9, 10 Knowing these results, select few surgeons and institutions continue to advance mini-MVR with expansion outside of low-risk degenerative mitral disease. There are now studies examining mini-MVR for multiple valve surgery, low ejection fraction, and obese, extremely elderly, and reoperative patients. [11] [12] [13] [14] [15] [16] [17] Considering the excellent outcomes associated with mini-MVR, significant impediments must exist to prevent further widespread adoption. This certainly includes the learning curve and need for a physician champion. 18 However, resource utilization also is a large concern. Hospitals must purchase specialized equipment, train nurses and anesthetists, and be willing to dedicate additional operating room time. Several studies have examined resource utilization with mini-MVR for simple degenerative repairs. [19] [20] [21] As mini-MVR expands into greater-risk and more complex surgeries, the studies should evaluate representative populations. Therefore, the purpose of this analysis was to examine the outcomes and resource utilization of mini-MVR and conventional approach in a representative mitral valve population.
METHODS

Patient and Cost Data
The University of Virginia Institutional Review Board approved this study with a waiver of patient consent due to its retrospective nature (Protocol #19762). Patient records were extracted from an institutional Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database between January 2011 and December 2016. Inclusion criteria were mitral valve surgery with or without tricuspid valve repair, atrial fibrillation surgery (ablation, left atrial appendage ligation), or atrial septal defect repair. Of the 680 mitral surgeries performed in this time period, patients were excluded for other concomitant cardiac surgery (n ¼ 197) or emergent status (n ¼ 8), resulting in a cohort of 478 cases. Patients were stratified by approach into either conventional sternotomy or minimally invasive by right minithoracotomy. STS data captured operative metrics including time in the room as well as incision, cardiopulmonary bypass, and crossclamp times. Standard STS definitions were used, including operative mortality (in-hospital or 30-day) and major morbidity (permanent stroke, prolonged ventilation, reoperation for any reason, renal failure, and deep sternal wound infection). 22 Patient-level STS data are merged with financial records obtained from the finance department. Every hospital charge is associated with a cost valuation that includes both direct and indirect costs. Direct costs include all operating costs, such as supplies, salaries, and equipment depreciation, whereas indirect costs are typically hospital-wide costs that are assigned to a department and recalculated quarterly. Both fixed and variable costs are incorporated, with variable costs statistically determined based on volume.
The total costs (direct þ indirect) of a department are then allocated to the services provided (by charge code) based on cost accounting studies performed every fiscal year by the cost accountant.
For each patient, the cost estimates for each charge code are categorized by International Classification of Diseases, Ninth and Tenth Revisions. Categorization buckets are based on those submitted with Uniform Billing (2004) forms. For this study, they were organized by individual components of the hospital stay (eg, operating room, intensive care, pharmacy, blood bank, etc). Cost estimates are summed to calculate a total episode cost for the hospitalization. All cost data are presented as 2016 equivalent dollars with conversion using the market basket for the Center for Medicare and Medicaid Services Inpatient Prospective Payment System that captures medical-related inflation.
Minimally Invasive Protocol
Patients are placed in a supine position with a bump under the right shoulder. The anesthetist places a right internal jugular vein central line with a Swan-Ganz catheter, as well as a 16-gauge long sheath prepped into the field for percutaneous superior vena cava cannulation. The femoral artery and vein are accessed via a small incision for arterial and inferior vena cava cannulation. A 4-cm right mini-thoracotomy in the fourth interspace is made with visualization aided by a 5-mm HD thoracoscope (Stryker Corp, Kalamazoo, Mich). After cannulation and exposure, a long 14-gauge cardioplegia cannula is placed in the proximal aorta and the aorta is directly crossclamped with a detachable crossclamp (Glauber clamp, LivaNova PLC, London, United Kingdom). Cardiac arrest is achieved with 1200 to 1500 mL of antegrade Del Nido cardioplegia and redosed every 45 to 60 minutes with 500 mL delivered antegrade only as needed. Del Nido solution is also used for valve testing to avoid washout of cardioplegia solution during valve repair. Surgical repair and replacement techniques are similar for both conventional and minimally invasive operations, although they vary by surgeon preference, with one surgeon performing all minimally invasive mitral valve operations. For both approaches, ablations were performed with cryotherapy and left atrial appendage ligation with either a clip device or suture ligation. Multimodal analgesia includes liposomal bupivacaine for all thoracotomy incisions. Demonstration of the minimally invasive protocol is provided in Video 1.
Statistical Analysis
Patients were matched in a 1:1 fashion for propensity to undergo minimally invasive approach. Demographics, comorbid conditions, and mitral VIDEO (Table E1) . Matching was performed with a nearest neighbor greedy algorithm without replacement. Balance among matched pairs was assessed by standardized mean difference, with adequate matching defined as a maximum of 20% ( Figure E1 ). The distribution of matched pairs was also representative of the entire cohort, as demonstrated in Figure E2 . Categorical variables are presented as number (percent) and continuous variables as mean AE standard deviation, except for non-normally distributed data, which are shown as median [interquartile range as 25th, 75th percentiles]. For the entire cohort, categorical variables were analyzed by the c 2 test and continuous variables by an independent t test or Mann-Whitney U test as appropriate. Among the matched cohort, matched pairs were analyzed by Wilcoxon signed-rank test or paired t test based on normality or McNemar test as appropriate. All analyses were performed with SAS, Version 9.4 (SAS Institute, Cary, NC) with significance set to a < 0.05.
RESULTS
Entire Unmatched Cohort
Of all patients who underwent mitral valve surgery, there were numerous baseline differences between those who had conventional compared with minimally invasive approaches (Table E2) . Patients who underwent surgery by a conventional approach had greater comorbid disease including diabetes, renal failure, chronic lung disease, cerebrovascular disease, coronary disease, and hypertension (all P<.05). In addition, the type of mitral disease differed, with the conventional approach more commonly used for patients with rheumatic, endocarditis, and ischemic mitral diseases, whereas the minimally invasive approach had a greater proportion of degenerative disease (all P < .05). Therefore, operative characteristics also differed by approach, with a greater rate of repair by mini-MVR and more atrial fibrillation surgery by sternotomy (all P <.05; Table E2 ).
Unadjusted results are shown in Table E3 . There was a lower rate of STS major morbidity with mini-MVR (9% vs 20%, P ¼ .0009), transfusion (9% vs 54%, P < .0001), and prolonged ventilation (4% vs 15%, P ¼ .003). Resource utilization was lower nearly across the board for patients undergoing mini-MVR, except for readmissions, implant, and supply costs. Patients undergoing mini-MVR had $19,776 lower mean hospital cost, in addition to shorter length of stay, time ventilated, fewer discharges to a facility, and fewer readmissions (all P <.05).
Matched Baseline and Operative Characteristics
After matching, patient characteristics were well balanced and demonstrated no significant differences in demographics, comorbid disease, or mitral disease etiology ( Table 1 ). The mean age was 62 years, and 43% were female. Importantly, there were no significant differences in mitral valve disease etiology, with 82% overall having degenerative mitral disease. Rates of mitral repair were not statistically different between mini-MVR and conventional approaches (80% vs 69%, P ¼ .10). The rate of concomitant tricuspid repair 9.5% overall and similar between groups.
Most outcomes were similar between groups with one mortality in the conventional group (Table 2 ) and similar rates of major morbidity (9.5% vs 10.8%, P ¼ .78). However, mini-MVR was associated with significantly fewer transfusions (11% vs 27%, P ¼ .01).
Resource utilization was largely balanced between groups with no significant difference in length of stay, discharges to a facility, or rates of readmission (Table 3) . Mini-MVR was associated with significantly fewer hours ventilated (3.7 vs 6.0, P < .0001). Operative times were longer for mini-MVR (291 vs 234 minutes, P < .0001), and translated to marginally greater operative costs ($7645 vs $7293, P ¼ .85). However, mini-MVR was associated with significantly lower blood and ancillary costs (both P ¼ .001). With offsetting costs, the total hospital costs were similar, as represented by the median ($40,237 vs 38,649) and mean total hospital costs ($49,703 vs $54,970). The distribution of costs is demonstrated in Figure 1 .
To better understand the drivers of total hospital cost, multivariable linear regression calculated the independent costs associated with surgical approach, mitral repair versus replacement and addition of tricuspid and ablation procedures (Table 4) . Neither minimally invasive approach (À$273, P ¼ .98) nor ablation (À1423, P ¼ .90) was a significant predictor of total hospital cost, whereas mitral replacement ($37,966, P ¼ .001) and tricuspid repair ($40,428, P ¼ .024) were independently associated with total hospital cost.
DISCUSSION
This study assessed the comparative effectiveness of mini-MVR versus the conventional approach on outcomes and resource utilization in a representative population that included nondegenerative mitral disease, atrial fibrillation surgery, and tricuspid repairs. Outcomes were excellent in both groups with a low mortality and morbidity (0.7% and 10%, respectively). Mini-MVR was associated with fewer transfusions and shorter duration of mechanical ventilation, which translated into lower blood and ancillary costs. These cost savings are offset by longer operative times leading to greater surgical costs with mini-MVR. With offsetting costs, the total hospital costs are equivalent for mini-MVR and conventional approach. Other resource utilization metrics, including discharge to a facility and readmission, are low in both groups. Minimally invasive approaches to mitral valve surgery are currently expanding into greater-risk and more heterogeneous patient populations. However, studies have mainly focused on repair of degenerative mitral disease. [19] [20] [21] Therefore, this study sought to analyze a representative cohort of patients to determine outcomes and resource utilization in this real-world greater-risk, more complex patient population. Although this study failed to demonstrate superior morbidity and mortality results with mini-MVR, this was primarily due to excellent outcomes in both groups. Finding a difference when the mortality rate is <1% will prove difficult no matter the study sample size. The most significant finding was a 41% reduction in blood transfusions. These reductions are consistent with previous studies examining isolated mitral valve surgery, suggesting a strong correlation that persists in a greaterrisk cohort. 1, 2, 5, 6, 23 Component cost analysis demonstrates lower transfusion rates resulting in lower blood costs, a $675 median savings for patients undergoing mini-MVR. Meanwhile, shorter ventilator times resulted in decreased ancillary costs, a $1007 median savings. Meanwhile, longer operative times and specialized supplies led to $352 greater median surgical costs and $400 greater median implant costs. Although they marginally increased costs, the longer operative, cardiopulmonary bypass, and crossclamp times did not translate into worse complication rates.
Looking at composite total hospital cost, the median total hospital cost was equivalent between groups, although it is important to look closely at the numbers. The high variance and skewed nature of the cost data resulted in the mean hospital cost being $4788 lower in the mini-MVR group and the median $2025 greater in the mini-MVR group. The multivariable analysis sheds some insight into these numbers, where tricuspid surgery and mitral replacement were significant predictors of total hospital cost. Previous research has demonstrated greater costs with mitral replacement versus repair, and this study found $37,000 associated with mitral replacement. 21, 24 Tricuspid surgery was also a strong predictor of cost in our model and accounted for more than $40,000 of total hospital cost. This may be in part due to collinearity with other risk factors as well as both being markers for a more complex patient at greater risk for complications, which is consistent with previous analyses. 24 Previous work has demonstrated that complications after surgery drive much of the cost variation and high cost outliers. [25] [26] [27] [28] Finally, costs increased significantly per year and supports previous work demonstrating that changing practices may have improved outcomes, but these interventions are costly. 29 This study is limited by its retrospective nature with inherent selection bias, which was mitigated by using careful propensity score matching. In addition, although based on surgeon training the repair techniques should be similar, there was not a protocol enforcing identical methods. As a single-center study at an academic center with thoracic residents performing much of the operations, the generalizability may be limited. The cost conversions are estimates based on charges that may be influenced by the case mix of the hospital and do not include physician charges; thus, they may not represent true cost for each patient. However, both direct and indirect cost estimates for charges are routinely updated by a dedicated costing department, providing high-quality and accurately categorized estimates. Finally, the low sample size limits the power of the study, although significant correlations that were identified suggest sufficient power for the limited conclusions that were drawn.
As clinical practice adapts to the increasing risk of mitral valve patients, studies should follow suit and include a representative cohort of complex mitral disease and concomitant procedures. In this analysis, we demonstrate that as patient complexity and risk increases, a minimally invasive approach continues to provide benefits such as reduced risk for transfusions and less time ventilated. These translate into lower associated costs with only marginally greater offsetting surgical costs that ultimately means equivalent total hospital cost. Importantly, drivers of cost are tricuspid valve surgery, mitral replacement, complications, and changing practices over time. Minimally invasive mitral surgery provides patients with excellent outcomes and resource utilization even in greater-risk, more-complex patients.
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